Posted in | News | Bionanotechnology

AuraSense Forms Advisory Board with Internationally Renowned Experts

AuraSense, a biotechnology company founded to pursue the unique therapeutic potential of engineered nanoparticles, announces the formation of their Advisory Board.

The company is very fortunate to have engaged a set of internationally renowned and highly qualified individuals in its mission to develop nanoparticle therapeutics. The members of the Advisory Board are five distinguished experts in Cancer, Cardiology, Gene Expression and Pharmaceuticals. They will advise AuraSense on furthering its scientific and commercial pursuits within its Gene Regulation, HDL and Intracellular Assay platforms.

AuraSense founder Dr. Chad A. Mirkin noted that: “The Advisory Board represents a world class group of scientists, clinicians, and business leaders who nicely complement the AuraSense team. We are now well-positioned to greatly accelerate our developments targeting oncology, cardiovascular, neurodegenerative, and anti-infective indications, among many others.”

Members of the AuraSense Advisory Board include:

Mark Booth

  • Chief Commercial Officer, Orexigen Therapeutics
  • Former President, Takeda Pharmaceuticals North America
  • Previously, Senior Vice President, General Manager at Immunex Corporation

William W. O’Neill, M.D., F.A.C.C., F.S.C.A.I.

  • Executive Dean for Clinical Affairs, Miller School of Medicine, University of Miami
  • Former Director of Cardiovascular Disease, William Beaumont Hospital, Royal Oak; Co-director of the Beaumont Heart Center, Royal Oak
  • Former Corporate Chief of Cardiology, William Beaumont Hospitals, Royal Oak and Troy

Bertram Pitt, M.D., F.A.C.C.

  • Professor of Medicine Emeritus, University of Michigan School of Medicine
  • Former Director, Division of Cardiology, University of Michigan School of Medicine
  • Former Chairman, Council on Circulation of the American Heart Association

Steven T. Rosen, M.D., F.A.C.P.

  • Genevieve Teuton Professor of Medicine, Feinberg School of Medicine, Northwestern University
  • Director of the Robert H. Lurie Comprehensive Cancer Center of Northwestern University; Director of Cancer Programs at Northwestern Memorial Hospital
  • Serves on multiple editorial boards and is editor-in-chief of Cancer Treatment & Research and Oncology News International

Erik J. Sontheimer, Ph.D.

  • Associate Professor, Department of Biochemistry, Molecular Biology, and Cell Biology, Northwestern University
  • Research focuses on the biochemical mechanisms of gene expression and gene control, with an emphasis on genetic interference pathways
  • B.S. in Molecular and Cell Biology, Penn State; Ph.D. in Molecular Biophysics and Biochemistry, Yale University; Fellowship at the University of Chicago (Jane Coffin Childs Memorial Fund)


Tell Us What You Think

Do you have a review, update or anything you would like to add to this news story?

Leave your feedback
Your comment type

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.